ライフサイエンスコーパス: DES

1 DES for percutaneous coronary intervention appears to be

2 DES outcomes in the Liberal era were significantly bette

3 DES showed a good solubility of phenolic compounds with

4 DES treatment outcomes in patients with versus without D

5 DES use varied, from 56% in the Transitional era to 85%

6 DES were associated with a lower incidence of myocardial

7 DES, compared with BMS, were associated with a significa

8 DES-PCI showed similar survival to SA-CABG except for a

9 DESs are green solvents characterized by high availabili

10 analysis by dividing the study period into 3 DES eras: Transitional (April 23, 2003, to June 30, 2004

11 ational Patient Register, we evaluated 4,303 DES-PCI-treated patients with a surgical procedure and c

12 207 BMS-PCI (age 66.6 +/- 11.9 years); 2,381 DES-PCI (age 65.9 +/- 11.7 years); 2,289 SA-CABG (age 69

13 A total of 537 patients (n=153 BRS; n=384 DES) were included.

14 Images were acquired in 61 patients (42 DES and 19 BMS) presenting with definite VLST.

15 aspirin, of whom 1687 received BMS and 9961 DES.

16 ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-E

17 METHODS AND ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-E

18 Among 8582 subjects in ADAPT-DES, 405 (4.7%) had SVG PCI.

19 bjects in the prospective, multicenter ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With

20 lar observational studies (PROMETHEUS, ADAPT-DES [the Assessment of Dual AntiPlatelet Therapy with Dr

21 The prospective ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-E

22 elet Therapy With Drug-Eluting Stents (ADAPT-DES) registry, which included 8582 patients undergoing p

23 elet Therapy With Drug-Eluting Stents (ADAPT-DES) study was a prospective, multicenter registry study

24 elet Therapy With Drug-Eluting Stents (ADAPT-DES) was a multicenter, prospective study in patients un

25 ternal validation was performed in the ADAPT-DES (Assessment of Dual Antiplatelet Therapy With Drug-E

26 compared 8448 patients enrolled in the ADAPT-DES study (Assessment of Dual Antiplatelet Therapy With

27 derwent successful PCI with DES in the ADAPT-DES study, PDB occurred in 535 of 8,577 hospital survivo

28 aluate the efficacy and safety of DAPT after DES implantation.

29 ncreased mortality with prolonged DAPT after DES implantation.

30 hat tested different durations of DAPT after DES implantation: shorter dual antiplatelet therapy (S-D

31 as only present within the first month after DES-PCI, suggesting that surgery might be undertaken ear

32 nts requiring surgery within 12 months after DES-PCI had an increased risk of MI and cardiac death co

33 Less minor amputations occurred after DES until 6 months post-treatment (P=0.03).

34 ear provides ischemic event protection after DES, ischemic event risk is perceived to be less after B

35 the minimum duration of DAPT required after DES implantation?

36 ogrel therapy from 6 months to 6 weeks after DES implantation was associated with a superior net clin

37 ssel revascularization were reduced with all DES compared with BMS, with cobalt-chromium EES, platinu

38 After a median follow-up of 3.8 years, all DES demonstrated superior efficacy compared with BMS.

39 Among DES, second-generation devices have substantially improv

40 hed cohort, no significant association among DES (vs BMS) use and outcomes was observed at 1 and 2 ye

41 Using instrumental variable analysis, DES were associated with no difference in 1-year mortali

42 ts with 239 lesions received BVS (n=112) and DES (n=127).

43 BMS and DES offer good clinical outcomes in this age group.

44 all 11,648 randomized patients (both BMS and DES), stent thrombosis rates were 0.41% vs 1.32% (n = 23

45 ces in target-vessel failure between BRS and DES (4.6% versus 7.7%; P=0.21).

46 l no significant differences between BRS and DES (hazard ratio, 1.54; 95% confidence interval, 0.69-3

47 was achieved in 99.3% and 96.6% of BRS- and DES-treated patients, respectively (P=0.07).

48 ry restenosis was comparable between BVS and DES (7.8% versus 8.9%; P=0.90).

49 duals receiving multilesion PCI with BVS and DES and follow-up angiography at 6 to 8 months were stud

50 s the intraindividual performance of BVS and DES in patients receiving multilesion PCI and follow-up

51 1.6%; P=0.48) did not differ between BVS and DES.

52 Kaplan-Meier estimates for CABG and DES did not significantly differ for mortality or mortal

53 ith 3-vessel or left main CAD, both CABG and DES-PCI were associated with substantial and sustained q

54 efficacy of EES in bare-metal stent ISR and DES-ISR.

55 and unplanned reintervention for BMS-PCI and DES-PCI to respective propensity-matched SA-CABG and MA-

56 cture is disrupted; instead, water-water and DES-water interactions dominate.

57 paring BP-BES versus currently U.S.-approved DES or BMS were searched through MEDLINE, EMBASE, and Co

58 cessfully treated with the randomly assigned DES (n=257) or BMS (n=255).

59 ion was performed and choline chloride-based DES containing oxalic acid as a hydrogen bond donor with

60 safety and efficacy of durable polymer-based DES, bioabsorbable polymer-based biolimus-eluting stents

61 Compared with BMS, DES implantation using a stent with a biocompatible poly

62 randomly assigned to biolimus-A9-eluting BP-DES, second-generation everolimus-eluting DP-DES, or thi

63 In large vessel stenting, BP-DES appeared barely noninferior compared with DP-DES and

64 iodegradable-polymer drug-eluting stents (BP-DES) were developed to be as effective as second-generat

65 By intention-to-treat BP-DES were noninferior (predefined margin, 3.80%) compared

66 ce of the primary end point was 7.6% with BP-DES, 6.8% with DP-DES, and 12.7% with BMS.

67 in events >1 year, particularly VLST with BP-DES.

68 isk was defined by a prior MI rather than by DES implantation, the primary analysis provides moderate

69 Compared with MA-CABG, DES-PCI exhibited worse survival at 5 (86.3% vs. 95.6%)

70 ed, patient-blinded, randomized, comparative DES trial that enrolled patients from June 18, 2008, to

71 Randomized controlled trials comparing DES to each other or to BMS were searched through MEDLIN

72 probability of treatment weighting to create DES- and BMS-treated groups whose observed baseline char

73 Current desensitization (DES) methods are not always effective.

74 tion [CMR], 38 no rejection in desensitized [DES] and non-DES control groups) for reverse transcripti

75 Desmin (DES) mutations cause severe skeletal and cardiac muscle

76 Prenatal exposure to diethylstilbestrol (DES) is known to cause an increased susceptibility to a

77 of prenatal exposure to diethylstilbestrol (DES), a potent endocrine disruptor, with incidence of ut

78 pionate (TP), estrogen - Diethystilbesterol (DES) and glucocorticoid - Dexamethasone (DEX)), only and

79 Initially, screening of five different DES for proposed extraction was performed and choline ch

80 DES, second-generation everolimus-eluting DP-DES, or thin-strut silicon-carbide-coated BMS in 8 Europ

81 , and TVR compared with second-generation DP-DES but higher rates of definite ST than CoCr-EES.

82 tion durable-polymer drug-eluting stents (DP-DES) and as safe >1 year as bare-metal stents (BMS).

83 (predefined margin, 3.80%) compared with DP-DES (absolute risk difference, 0.78%; -1.93% to 3.50%; P

84 appeared barely noninferior compared with DP-DES and more effective than thin-strut BMS, but without

85 end point was 7.6% with BP-DES, 6.8% with DP-DES, and 12.7% with BMS.

86 Five (E2, DES, DPN, BPAF, Coum, 1-BP) of 16 compounds tested by re

87 rization for multivessel disease with either DES or isolated CABG (n=893 each group) were analyzed.

88 The curcumin concentration in enriched DES phase was analyzed by UV-Visible spectrophotometer.

89 Mean time to transplant from first DES was 25 +/- 10.5 months but after TCZ was 8.1 +/- 5.4

90 total of 11,026 operations (66.3%) followed DES placement, and 5608 (33.7%) followed bare metal sten

91 s that showed decreased expression following DES treatment, miR-18b and miR-23a were found to possess

92 Six-month patency rates were 48.0% for DES and 35.1% for PTA+/-BMS (P=0.096) in the modified-in

93 k of 1-year MACE in uncertain candidates for DES implantation.

94 teria, qualified as uncertain candidates for DES, to receive ZES or BMS.

95 h those of 155 patients treated with EES for DES-ISR.

96 red in this study will contribute to further DES implementation in extraction of biologically active

97 correlates included use of early generation DES (HR=1.75, P=0.02), no procedural intravascular ultra

98 ]) compared with the use of first-generation DES (OR: 3.94 [95% CI: 2.20 to 7.05]; p for interaction

99 comes compared with BMS and first-generation DES and similar rates of cardiac death/MI, MI, and TVR c

100 randomly assigned to have a first-generation DES implanted.

101 BMS) and indirect evidence (first-generation DES with BMS and second-generation DES) from the randomi

102 received BMS, 15% received first-generation DES, and 47% received second-generation DES.

103 ccording to stent use: BMS, first-generation DES, and newer generation DES group.

104 ng bare-metal stents (BMS), first-generation DES, and newer generation DES in a large unselected nati

105 .68; P<0.001), but not with first-generation DES, compared with BMS-treated patients.

106 eneration DES, but not with first-generation DES, compared with the patients treated with BMS.

107 ials comparing stent types (first-generation DES, second-generation DES or BMS) were considered for i

108 patients with DM receiving first-generation DES.

109 r DES platforms compared to first-generation DES.

110 24-month DAPT after PCI with new-generation DES in good aspirin responders.

111 , first-generation DES, and newer generation DES group.

112 , first-generation DES, and newer generation DES in a large unselected national data set from the BCI

113 DAPT after implantation of newer-generation DES and in secondary prevention after MI.

114 d efficacy of BP-BES versus newer-generation DES coated with more biocompatible DP have not been inve

115 DAPT after implantation of newer-generation DES entails a tradeoff between reductions in stent throm

116 who received predominantly newer-generation DES to answer: A1) Use of DAPT for 12 months, as compare

117 g stent (DES) platforms, previous generation DES, and bare-metal stents (BMS) for percutaneous corona

118 r in patients treated with second-generation DES (odds ratio, 0.51; 95% confidence interval, 0.38-0.6

119 attenuated with the use of second-generation DES (OR: 1.54 [95% CI: 0.96 to 2.47]) compared with the

120 Patients receiving second-generation DES for the treatment SVG disease have lower rates of in

121 Implantation of BRS versus second-generation DES in chronic total occlusion was associated with simil

122 pes (first-generation DES, second-generation DES or BMS) were considered for inclusion.

123 pool direct (comparison of second-generation DES to BMS) and indirect evidence (first-generation DES

124 eneration DES with BMS and second-generation DES) from the randomized trials.

125 attenuated with the use of second-generation DES, although the analysis may have been limited by the

126 r in patients treated with second-generation DES, but not with first-generation DES, compared with th

127 tion in patients receiving second-generation DES.

128 coronary intervention with second-generation DES.

129 tion DES, and 47% received second-generation DES.

130 ar safety and efficacy of 2 newer-generation DESs in randomized participants with non-ST-elevation ac

131 safety and efficacy of the newer-generation DESs used.

132 he determinations of D and k(0) in glyceline DES by voltammetric studies using the Nicholson approach

133 in disease or a SYNTAX score </=22, however, DES-PCI was economically dominant compared with CABG, al

134 antiproliferative drugs for achieving ideal DES performance.

135 Cox regression analysis identified DES use to be associated with greater hazard for late mo

136 sis was frequently observed in BMS (40.5% in DES and 68.4% in BMS; P=0.056).

137 pansion were more frequently demonstrated in DES than in BMS patients, whereas neoatherosclerosis was

138 frames with neoatherosclerosis was lower in DES than in BMS (15.56% [12.24-28.57] versus, 56.41% [40

139 cutive lipid neointima length was shorter in DES than in BMS (2.4 [1.2-3.6] and 5.3 [3.0-7.0] mm; P=0

140 Surgery in DES-PCI-treated patients was associated with an increase

141 tomography imaging demonstrated that VLST in DES and BMS had a wide variety of abnormal findings, suc

142 Comparing RLi reactivities in DESs with those observed in pure glycerol or THF suggest

143 he expression of myogenic markers, including DES, MYOG, MYH1, and MF20.

144 stent by percutaneous coronary intervention (DES-PCI).

145 b ischemia caused by infrapopliteal lesions, DES provide better 6-month patency rates and less amputa

146 New-generation metallic DES (EES/BES) were not superior to BVS in terms of angio

147 t and intense with the BVS than the metallic DES and could be determined by patient baseline characte

148 Finally, the p.Glu401Asp mutated DES gene was transfected into cell lines and analyzed by

149 ) with new-generation drug-eluting stents (n-DES) compared with bare-metal stents (BMS) and old-gener

150 of early/late ST in patients treated with n-DES (hazard ratio [HR]: 0.65; 95% confidence interval [C

151 8 no rejection in desensitized [DES] and non-DES control groups) for reverse transcription into cDNA,

152 ps (P < 0.01 vs DES control, P < 0.05 vs non-DES control).

153 We identified the novel DES mutation p.Glu401Asp in a large Spanish family with

154 scribe clinically and functionally the novel DES-p.Glu401Asp mutation as a cause of inherited left ve

155 interval [CI]: 0.43 to 0.99; p = 0.04) and o-DES (HR: 0.60; 95% CI: 0.41 to 0.89; p = 0.01) compared

156 S) and old-generation drug-eluting stents (o-DES) enrolled in the SCAAR (Swedish Coronary Angiography

157 er 31, 2010, and examined the association of DES versus BMS with 1-year outcomes: death; death or MI;

158 ed the long-term quality-of-life benefits of DES-PCI versus CABG for patients with 3-vessel or left m

159 The spectrophotometric characteristics of DES extracts of 65 EVOO samples were related to the tota

160 Different combinations of DES consisting of choline chloride (ChCl) in various mix

161 ffect of parameters such as pH, mol ratio of DES composition, volume of DES, volume of tetrahydrofura

162 is best described as an aqueous solution of DES components.

163 re, we undertook a phase I/II pilot study of DES using a novel drug (anti-IL-6 receptor (IL-6R),Tocil

164 we observed widespread and increasing use of DES during SVG-PCI.

165 pH, mol ratio of DES composition, volume of DES, volume of tetrahydrofuran (THF) and sample volume w

166 ions were randomized to receive PTA+/-BMS or DES with paclitaxel.

167 3-vessel or left main CAD to either CABG or DES-PCI.

168 ularization, compared with either BMS-PCI or DES-PCI, resulted in substantially enhanced death and re

169 very and enrichment factor compared to other DESs.

170 kidney transplant recipients undergoing PCI, DES was associated with better clinical outcomes beyond

171 ll persists with newer biodegradable polymer DES generations against second-generation permanent poly

172 h the early generation biodegradable polymer DES platforms compared to first-generation DES.

173 A variety of biodegradable polymer DES platforms have been clinically tested, showing equal

174 against second-generation permanent polymer DES needs to be explored.

175 s with the standard-bearer permanent polymer DES within the first year of implantation.

176 prior history of UL or cancer, and prenatal DES exposure.

177 These data demonstrated that prenatal DES exposure can cause alterations in miRs, leading to c

178 enge (P = 0.0007) observed, whereas prenatal DES or DEX treatment had no effects upon insulin secreti

179 Desensitization protocols (DES) have evolved, but rigorous evaluation is lacking.

180 ecember 2010; 2400 and 845 patients received DES and BMS, respectively.

181 atients with noninsulin-treated DM receiving DES, prolonged clopidogrel treatment was associated with

182 y and correlates of ST in patients receiving DES, specifically examining the impact of risk factors m

183 Recently, DES mutations were described in patients with inherited

184 erwent nonrandomized treatment with the same DESs.

185 lled eligible patients treated with the same DESs.

186 itions inducing dermal-epidermal separation (DES).

187 domain, downstream ETO-interacting sequence (DES), for corepressor-mediated repression.

188 raction (DLLME) using deep eutectic solvent (DES) as the extracting solvent has been developed and ap

189 A natural deep eutectic solvent (DES) based on glucose and lactic acid was considered as

190 Deep eutectic solvent (DES) formed by mixing of choline chloride and phenol was

191 rape skin phenolics, deep eutectic solvents (DES) as a green alternative to conventional solvents cou

192 Deep eutectic solvents (DESs) are "green" solvents, applied in this study for th

193 green, biorenewable deep eutectic solvents (DESs) at room temperature and in the presence of air, es

194 The utilization of deep eutectic solvents (DESs) in electrochemical studies has grown in recent yea

195 ntion using contemporary drug-eluting stent (DES) compared with coronary artery bypass graft (CABG) s

196 b BVS or Xience metallic drug-eluting stent (DES) implantation (Abbott Vascular, Santa Clara, Califor

197 intervention (PCI) with drug-eluting stent (DES) implantation are unclear.

198 lowing second-generation drug-eluting stent (DES) implantation is still debated.

199 let therapy (DAPT) after drug-eluting stent (DES) implantation is unclear, and its risks and benefits

200 lation (OAC) who undergo drug-eluting stent (DES) implantation require additional dual antiplatelet t

201 eatment of patients with drug-eluting stent (DES) in-stent restenosis (ISR) is more challenging than

202 eatment of patients with drug-eluting stent (DES) in-stent restenosis (ISR) remains a major challenge

203 esion complexity affects drug-eluting stent (DES) outcomes according to diabetic status.

204 let therapy (DAPT) after drug-eluting stent (DES) placement remains controversial.

205 necessity of polymers on drug-eluting stent (DES) platforms is dictated by the need of an adequate am

206 mparison of contemporary drug-eluting stent (DES) platforms, previous generation DES, and bare-metal

207 atelet therapy (DAPT) in drug-eluting stent (DES) recipients is 12 months to reduce the risk of late

208 we identified quarterly drug-eluting stent (DES) use rates as an instrumental variable.

209 ld (BVS) versus drug-eluting metallic stent (DES) in the same individual receiving multilesion percut

210 rst-generation drug-eluting coronary stents (DES) were introduced in 2003 to 2004, and their use resu

211 us durable-polymer (DP)-drug-eluting stents (DES) and bare-metal stents (BMS) by means of a network m

212 s of different types of drug-eluting stents (DES) and bare-metal stents (BMS); however, most prior tr

213 ts and early-generation drug-eluting stents (DES) and have not systematically evaluated the role of i

214 ) after implantation of drug-eluting stents (DES) are incompletely understood.

215 ) and second-generation drug-eluting stents (DES) at 5 institutions.

216 ic efficacy of coronary drug-eluting stents (DES) compared with bare metal stents (BMS), the relative

217 erventional cardiology, drug-eluting stents (DES) have shown better patency rates and are standard pr

218 The use of drug-eluting stents (DES) in patients at high risk of bleeding or thrombosis

219 ary intervention (PCI), drug-eluting stents (DES) reduce repeat revascularizations compared with bare

220 ion of newer-generation drug-eluting stents (DES) remains uncertain.

221 intervention (PCI) with drug-eluting stents (DES) versus bare metal stents (BMS) has not been studied

222 ons similar to metallic drug-eluting stents (DES), followed by complete bioresorption in approximatel

223 intervention (PCI) with drug-eluting stents (DES), improvements driven mainly by differences in myoca

224 th insulin who received drug-eluting stents (DES), prolonged clopidogrel treatment was associated wit

225 -metal stents (BMS) and drug-eluting stents (DES).

226 ersus the best-in-class drug-eluting stents (DES).

227 e-metal stents (BMS) or drug-eluting stents (DES).

228 y disease in the era of drug-eluting stents (DES).

229 raft (SVG) lesions with drug-eluting stents (DES; paclitaxel- or everolimus-eluting stents) for reduc

230 -used, newer-generation drug-eluting stents (DESs) in a broad patient population is of interest.

231 After successful DES implantation, ST occurred within 2 years in 1.1% of

232 y further improve prognosis after successful DES implantation.

233 significantly different in the 2 groups (SVG-DES: 15.0%, SVG-MT: 20.0%; hazard ratio, 0.65; 95% confi

234 re randomized (1:1) to DES implantation (SVG-DES) or medical treatment (SVG-MT) of the target SVG les

235 n MACE related to the target SVG lesion (SVG-DES: 10.0%, SVG-MT: 16.9%; hazard ratio, 0.53; 95% confi

236 rval, 0.20-1.43; P=0.21) or global MACE (SVG-DES: 36.7%, SVG-MT: 44.6%; hazard ratio, 0.73; 95% confi

237 ty and 65 patients were allocated to the SVG-DES and SVG-MT groups, respectively.

238 time horizon, CABG remained more costly than DES-PCI, but the incremental cost-effectiveness ratio wa

239 Transfection studies confirmed that DES-mediated downregulation of miR-18b and miR-23a led t

240 gested a paradigm shift from the notion that DES are less safe than BMS to the converse.

241 er analyses in the fetuses, we observed that DES-mediated changes in miR expression may regulate gene

242 Our results suggest that DES offers an efficient, safe, sustainable, and cost eff

243 The DES-p.Glu401Asp mutation causes predominant inherited le

244 his segregation becomes unfavorable, and the DES structure is disrupted; instead, water-water and DES

245 in explanted cardiac tissue affected by the DES mutation.

246 Of the 66 family members screened for the DES-p.Glu401Asp mutation, 23 of them were positive, 6 we

247 However, the DES nanostructure is retained to a remarkably high level

248 to VLST presentation was 51.4 months in the DES and 69.9 months in the BMS group (P=0.011).

249 he BMS group versus 14.3% of patients in the DES group (p = 0.09).

250 major amputation rate remained lower in the DES group until 2 years post-treatment, with a trend tow

251 ion (8 versus 2%, P=0.03) were higher in the DES-ISR group.

252 us 2.38+/-0.5 mm, P=0.01) was smaller in the DES-ISR group.

253 At and above this hydration level, the DES-water mixture is best described as an aqueous soluti

254 The yields of the DES extractions were compared with those from convention

255 even at low hydration levels, reporting the DES water content is important.

256 Therefore the DES could provide a promising and viable approach for a

257 icantly greater with the BVS compared to the DES (6.7 +/- 12.6% vs. 2.9 +/- 11.5%; p = 0.003); the re

258 and cultured from 2 family members with the DES mutation (1 with mild and 1 with severe symptomatolo

259 PhAA/TMG DES achieved higher recovery and enrichment factor compa

260 Patients were randomized (1:1) to DES implantation (SVG-DES) or medical treatment (SVG-MT)

261 its risks and benefits may vary according to DES generation.

262 d, pregnant C57BL/6 mice who were exposed to DES and miR profiles in thymocytes of both the mother an

263 Risk was strongest for women exposed to DES in the first trimester, when exposure corresponds to

264 atory demonstrated that prenatal exposure to DES induces thymic atrophy and apoptosis in the thymus.

265 At 5-year follow-up, CABG was superior to DES-PCI on several SAQ domains including angina frequenc

266 o November 2013, 10 patients unresponsive to DES with IVIg + Rituximab were treated with IVIg + TCZ.

267 d 2012, a total of 22,590 patients underwent DES-PCI in western Denmark.

268 nrolled patients receiving OAC who underwent DES implantation at 3 European centers between September

269 ith percutaneous coronary intervention using DES in patients with chronic kidney disease undergoing i

270 her percutaneous coronary intervention using DES or CABG between October 1, 2008, and September 30, 2

271 ounds have been extracted from VOO oil using DES.

272 0 patients were treated with either XIENCE V DES (n=51) or BMS postdilated with the SeQuent Please DE

273 worse treatment failure for PTA+/-BMS versus DES (P=0.041).

274 umen loss in lesions treated with BVS versus DES (0.30+/-0.59 versus 0.22+/-0.48 mm; P=0.035).

275 and no rejection control groups (P < 0.01 vs DES control, P < 0.05 vs non-DES control).

276 tly have complex coronary disease warranting DES but have a higher risk of bleeding from prolonged du

277 omized trial was conducted to assess whether DES also improve patency and clinical outcome of infrapo

278 o evaluate the surgical risk associated with DES-PCI compared with that in nonstented patients withou

279 ive revascularization strategy compared with DES-PCI.

280 longitudinal extension in BMS compared with DES.

281 le intraindividual performance compared with DES.

282 ring percutaneous coronary intervention with DES and with BMS in dialysis patients.

283 rgoing successful coronary intervention with DES in whom routine platelet reactivity testing was perf

284 intermediate nonobstructive SVG lesions with DES was safe but was not associated with a significant r

285 h-risk, inpatient surgery, and patients with DES may benefit most from delay from a 6-month delay aft

286 A total of 309 patients with DES-ISR from 23 Spanish university hospitals were random

287 f EES are less satisfactory in patients with DES-ISR than in those with bare-metal stent ISR.

288 teristics were more adverse in patients with DES-ISR, although they presented later and more frequent

289 In patients with DES-ISR, EES provided superior long-term clinical and an

290 ained significantly smaller in patients with DES-ISR.

291 /-17%, P<0.001) were poorer in patients with DES-ISR.

292 After successful PCI with DES in an unrestricted patient population, PDB is not un

293 ll-comers" who underwent successful PCI with DES in the ADAPT-DES study, PDB occurred in 535 of 8,577

294 ischemic and bleeding events after PCI with DES, thereby facilitating clinical decisions surrounding

295 ts with PLAD who underwent CABG and PCI with DES.

296 ing stents (EES) in patients presenting with DES-ISR.

297 y-four limbs (73 patients) were treated with DES and 66 limbs (64 patients) received PTA+/-BMS.

298 ss of the Tryton Side Branch Stent Used With DES in Treatment of de Novo Bifurcation Lesions in the M

299 ss of the Tryton Side Branch Stent Used With DES in Treatment of de Novo Bifurcation Lesions in the M

300 However, at 3 years, DES was associated with 20% (95% confidence interval [CI